Mike Mattie

793 total citations
17 papers, 223 citations indexed

About

Mike Mattie is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Mike Mattie has authored 17 papers receiving a total of 223 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 5 papers in Immunology and 2 papers in Molecular Biology. Recurrent topics in Mike Mattie's work include CAR-T cell therapy research (15 papers), Immunotherapy and Immune Responses (3 papers) and Viral Infectious Diseases and Gene Expression in Insects (2 papers). Mike Mattie is often cited by papers focused on CAR-T cell therapy research (15 papers), Immunotherapy and Immune Responses (3 papers) and Viral Infectious Diseases and Gene Expression in Insects (2 papers). Mike Mattie collaborates with scholars based in United States, France and Germany. Mike Mattie's co-authors include Pia M. Challita-Eid, Yuriy Shostak, Alla Verlinsky, Karen Morrison, Ingrid B.J. Joseph, Zili An, Yi Zhang, David R. Stover, Ashley Christensen and Mi Sook Chang and has published in prestigious journals such as Journal of Clinical Investigation, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Mike Mattie

15 papers receiving 219 citations

Peers

Mike Mattie

ONCOL

IMMUN

Changcan Li China

Joseph Tang United Kingdom

Inês Mota Portugal

Kazuhiro Togasaki Japan

Zhijian Ren China

Hordur M. Kolbeinsson United States

Ryan Massa United States

Yibin Lin China

Guoxiang Fu China

Changcan Li China

Mike Mattie

97 ×0.7

ONCOL

164 ×3.0

63 ×1.1

38 ×0.9

24 ×0.7

IMMUN

Citations per year, relative to Mike Mattie Mike Mattie (= 1×) peers Changcan Li

Countries citing papers authored by Mike Mattie

Since Specialization

Citations

This map shows the geographic impact of Mike Mattie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mike Mattie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mike Mattie more than expected).

Fields of papers citing papers by Mike Mattie

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mike Mattie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mike Mattie. The network helps show where Mike Mattie may publish in the future.

Co-authorship network of co-authors of Mike Mattie

This figure shows the co-authorship network connecting the top 25 collaborators of Mike Mattie. A scholar is included among the top collaborators of Mike Mattie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mike Mattie. Mike Mattie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Locke, Frederick L., Nathalie Scholler, Mike Mattie, et al.. (2025). Facts and Hopes: CAR T-Cell Therapy and Immune Contexture in Non-Hodgkin Lymphoma. Clinical Cancer Research. 31(18). 3834–3843.

Cheloni, Giulia, Dimitra Karagkouni, Yered Pita-Juárez, et al.. (2025). Durable response to CAR T is associated with elevated activation and clonotypic expansion of the cytotoxic native T cell repertoire. Nature Communications. 16(1). 4819–4819.

Speth, Kelly, Jin Xie, Qinghua Song, et al.. (2025). Classification of patients with relapsed/refractory large B-cell lymphoma who do not develop early CRS/NE toxicity using ZUMA clinical trial data. Journal for ImmunoTherapy of Cancer. 13(8). e011819–e011819. 1 indexed citations

Balagurunathan, Yoganand, Jin Qi, Zachary Thompson, et al.. (2024). Radiomic features of PET/CT imaging of large B cell lymphoma lesions predicts CAR T cell therapy efficacy. Frontiers in Oncology. 14. 1485039–1485039. 2 indexed citations

Nayak, Lakshmi, Ugonma Chukwueke, Christopher Meehan, et al.. (2024). A pilot study of axicabtagene ciloleucel (axi-cel) for relapsed/refractory primary and secondary central nervous system lymphoma (PCNSL and SCNSL).. Journal of Clinical Oncology. 42(16_suppl). 2006–2006. 9 indexed citations

Jain, Michael D., David B. Miklos, Caron A. Jacobson, et al.. (2023). Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11. Clinical Cancer Research. 29(20). 4118–4127. 6 indexed citations

Mattie, Mike, Aurélie Auguste, Frederick L. Locke, et al.. (2023). Pre- and Post-Treatment Immune Contexture Correlates with Long Term Response in Large B Cell Lymphoma Patients Treated with Axicabtagene Ciloleucel (axi-cel). Blood. 142(Supplement 1). 226–226. 1 indexed citations

Mattie, Mike, et al.. (2023). Advancing CAR-T Therapy in Acute Lymphoblastic Leukemia: Multi-Omic Analyses of CD19-Directed CAR-T Cells Enabled By an Ex Vivo Co-Culture Platform. Blood. 142(Supplement 1). 244–244. 2 indexed citations

Raj, Sandeep, Jin Xie, Teng Fei, et al.. (2023). An Inflammatory Biomarker Signature Reproducibly Predicts CAR-T Treatment Failure in Patients with Aggressive Lymphoma across the Zuma Trials Cohorts. Blood. 142(Supplement 1). 224–224. 3 indexed citations

10.

Romain, Gabrielle, Paolo Strati, Ali Rezvan, et al.. (2022). Multidimensional single-cell analysis identifies a role for CD2-CD58 interactions in clinical antitumor T cell responses. Journal of Clinical Investigation. 132(17). 36 indexed citations

11.

Korell, Felix, Olaf Penack, Mike Mattie, et al.. (2022). EASIX and Severe Endothelial Complications After CD19-Directed CAR-T Cell Therapy—A Cohort Study. Frontiers in Immunology. 13. 877477–877477. 32 indexed citations

12.

Menges, Meghan, et al.. (2022). CAR-T manufactured from frozen PBMC yield efficient function with prolonged in vitro production. Frontiers in Immunology. 13. 1007042–1007042. 10 indexed citations

13.

Gerdemann, Ulrike, James J. Kaminski, Alexandre Albanese, et al.. (2022). Targeting CNS Lymphoma with Intravenous Axicabtagene Ciloleucel: Evidence for Transcriptional Evolution Towards a Prominent Interferon Signature in CAR-T Cells Trafficking to the Tumor Site. Blood. 140(Supplement 1). 408–409. 3 indexed citations

14.

Mattie, Mike, Frederick L. Locke, Sattva S. Neelapu, et al.. (2022). 1454 Multiomics and multimodal analysis approach to construct a diffuse large B cell lymphoma atlas of tumor microenvironment for predictive modeling. Regular and Young Investigator Award Abstracts. A1513–A1513. 1 indexed citations

15.

Cheloni, Giulia, Dina Stroopinsky, Dimitra Karagkouni, et al.. (2021). Profiling the Peripheral Blood Immune Cell Repertoire in Large-B Cell Lymphoma Patients Treated with CD19 CAR-T. Blood. 138(Supplement 1). 2786–2786. 1 indexed citations

16.

Mattie, Mike, Ashley Christensen, Mi Sook Chang, et al.. (2013). Molecular Characterization of Patient-Derived Human Pancreatic Tumor Xenograft Models for Preclinical and Translational Development of Cancer Therapeutics. Neoplasia. 15(10). 1138–IN17. 74 indexed citations

17.

Chan, June M., Vivian Weinberg, Mark Jesus M. Magbanua, et al.. (2010). Nutritional supplements, COX-2 and IGF-1 expression in men on active surveillance for prostate cancer. Cancer Causes & Control. 22(1). 141–150. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact